Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial

Introduction: Patients with primary hyperoxaluria type 1 (PH1), a genetic disorder associated with hepatic oxalate overproduction, frequently experience recurrent kidney stones and worsening kidney function. Lumasiran is indicated for the treatment of PH1 to lower urinary and plasma oxalate (POx). M...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff, Yaacov Frishberg, Hadas Shasha-Lavsky, Daniella Magen, Shabbir H. Moochhala, Eva Simkova, Martin Coenen, Wesley Hayes, Julien Hogan, Anne-Laure Sellier-Leclerc, Richard Willey, John M. Gansner, Sally-Anne Hulton
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:Kidney International Reports
Subjects:
lumasiran
oxalate
primary hyperoxaluria type 1
rare disease
renal
RNA interference
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924016838
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468024924016838

Similar Items